Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
S&P 500   3,963.94
DOW   33,849.46
QQQ   282.71
Wall Street slips as lockdown protests spread in China
This Govt. Act Can Help Investors (Ad)
China virus protests hit Hong Kong after mainland rallies
Is Snowflake Poised for A Rebound After Its Recent Tumble?
This Govt. Act Can Help Investors (Ad)
Need To Cut Costs? Start With These 10 Money Saving Ideas
Check Into The Hotel Rebound With These Welcoming Stocks
This Govt. Act Can Help Investors (Ad)
Impeachment talk at Trump Org. trial: Did witness misspeak?
'Gaslighting' is Merriam-Webster's word of the year for 2022
NASDAQ:ZEAL

Zealand Pharma A/S - ZEAL Price Target & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$17.59
$17.59
50-Day Range
$16.54
$19.20
52-Week Range
$9.93
$32.94
Volume
N/A
Average Volume
4,965 shs
Market Capitalization
$818.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Zealand Pharma A/S Consensus Rating and Price Target (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 2 Analyst Ratings

Consensus Analyst Price Target

N/A

TypeCurrent
11/29/21 to 11/29/22
1 Month Ago
10/30/21 to 10/30/22
3 Months Ago
8/31/21 to 8/31/22
1 Year Ago
11/29/20 to 11/29/21
Consensus Rating
Moderate Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
N/A
Hold
1 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price TargetN/AN/AN/AN/A
Predicted UpsideN/AN/AN/AN/A
Get Zealand Pharma A/S Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ZEAL and its competitors with MarketBeat's FREE daily newsletter.


ZEAL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZEAL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zealand Pharma A/S Stock vs. The Competition

TypeZealand Pharma A/SMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside746.83% Upside14.69% Upside
News Sentiment RatingPositive News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
290
65.61%
Underperform Votes
152
34.39%
Avg. Outperform Votes
163
66.26%
Avg. Underperform Votes
83
33.74%
Avg. Outperform Votes
853
68.19%
Avg. Underperform Votes
398
31.81%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/16/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight
1/11/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
8/13/2020Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Alan Carr
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00+17.25%
(Data available from 11/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












ZEAL Price Target - Frequently Asked Questions

What is Zealand Pharma A/S's consensus rating?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Zealand Pharma A/S stock is Moderate Buy based on the current 1 hold rating and 1 buy rating for ZEALthe . Learn more on ZEAL's analyst rating history.

Do Wall Street analysts like Zealand Pharma A/S more than its competitors?

Analysts like Zealand Pharma A/S less than other Medical companies. The consensus rating for Zealand Pharma A/S is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how ZEAL compares to other companies.

Do MarketBeat users like Zealand Pharma A/S more than its competitors?

MarketBeat users like Zealand Pharma A/S less than other Medical companies. 65.61% of MarketBeat users gave Zealand Pharma A/S an outperform vote while medical companies recieve an average of 66.40% outperform votes by MarketBeat users.

Is Zealand Pharma A/S being downgraded by Wall Street analysts?

Over the previous 90 days, Zealand Pharma A/S's stock had 1 downgrade by analysts.

What analysts cover Zealand Pharma A/S?

Zealand Pharma A/S has been rated by Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:ZEAL) was last updated on 11/29/2022 by MarketBeat.com Staff